We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

157 hedge funds and large institutions have $1.99B invested in Immunomedics Inc in 2017 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 58 increasing their positions, 48 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $168M | Put options by funds: $84.2M

25% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 28

23% more capital invested

Capital invested by funds: $1.62B → $1.99B (+$370M)

21% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 48

5% more funds holding

Funds holding: 150157 (+7)

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

Holders
157
Holders Change
+7
Holders Change %
+4.67%
% of All Funds
3.56%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.2%
New
35
Increased
58
Reduced
48
Closed
28
Calls
$168M
Puts
$84.2M
Net Calls
+$84.1M
Net Calls Change
+$43.5M
Name Holding Trade Value Shares
Change
Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$260M +$15.6M +1,325,000 +9%
BlackRock
2
BlackRock
New York
$146M +$8.69M +736,608 +9%
O
3
OrbiMed
New York
$137M -$18.1M -1,535,089 -15%
ACP
4
Acuta Capital Partners
California
$109M +$145K +12,294 +0.2%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$107M +$2.97M +251,530 +4%
State Street
6
State Street
Massachusetts
$103M +$19.4M +1,645,878 +35%
Millennium Management
7
Millennium Management
New York
$102M +$39.9M +3,376,764 +116%
Vanguard Group
8
Vanguard Group
Pennsylvania
$87M +$8.42M +713,620 +15%
ACH
9
ArrowMark Colorado Holdings
Colorado
$84.4M +$20.1M +1,705,624 +48%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$77.3M -$8.46M -716,400 -13%
PAI
11
Palo Alto Investors
California
$77.2M +$20.8M +1,763,795 +59%
Citadel Advisors
12
Citadel Advisors
Florida
$71.6M +$38.6M +3,270,177 +281%
NMC
13
NEA Management Company
Maryland
$44.8M
FCMI
14
Foresite Capital Management III
California
$43.6M +$3.78M +320,633 +13%
Jennison Associates
15
Jennison Associates
New York
$29.6M +$227K +19,195 +1%
PAMU
16
Pictet Asset Management (UK)
United Kingdom
$26.2M +$6.11M +517,611 +47%
GTC
17
Ghost Tree Capital
New York
$24.9M -$4.83M -408,946 -21%
Janus Henderson Group
18
Janus Henderson Group
United Kingdom
$24.5M +$17.9M +1,518,335 New
DM
19
Deerfield Management
New York
$21M +$8.48M +718,448 +123%
Northern Trust
20
Northern Trust
Illinois
$20.2M -$61.8K -5,234 -0.4%
Victory Capital Management
21
Victory Capital Management
Texas
$17.9M +$13.1M +1,110,192 New
FCMI
22
Foresite Capital Management IV
California
$17.3M +$12.7M +1,073,272 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$16.1M +$996K +84,407 +9%
FLAM
24
First Light Asset Management
Minnesota
$15.3M -$4.33M -367,110 -28%
Lord, Abbett & Co
25
Lord, Abbett & Co
New Jersey
$15.2M -$2.28M -193,394 -17%

IMMU Hedge Fund Activity: Q4 2017 in Review

157 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q4 2017, worth a combined $1.99B — up 23% from $1.62B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new IMMU positions and 28 closed out — a net gain of 7 holders — while 58 added to existing stakes and 48 trimmed.

The largest buyer was Millennium Management, adding an estimated $39.9M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $40M sold.

  • 157 institutional investors held Immunomedics Inc (IMMU) as of Q4 2017, up from 150 in Q3 2017.
  • Funds reported $1.99B of Immunomedics Inc stock for Q4 2017, up 23% quarter-over-quarter.
  • 35 funds opened new Immunomedics Inc positions in Q4 2017 and 28 closed out, a net change of +7 holders.
  • The largest Immunomedics Inc buyer in Q4 2017 was Millennium Management, an estimated $39.9M added.
  • The largest Immunomedics Inc seller in Q4 2017 was EcoR1 Capital, an estimated $40M sold.

Based on aggregated 13F filings for Q4 2017.